Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations | MicrobiomeTrials← Back to trialsNCT06581432
Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2024-10-11Est. Completion: 2027-12-31
Enrollment target: 430 participants Locations- Alaska Oncology and Hematology, LLC, Anchorage, Alaska, United States
- University of Arizona Comprehensive Cancer Center, Tucson, Arizona, United States
- Precision NextGen Oncology, Beverly Hills, California, United States
- Scripps Cancer Center Torrey Pines, La Jolla, California, United States
- Valkyrie Clinical Trials, Los Angeles, California, United States
- Yale University School of Medicine, New Haven, Connecticut, United States
- BRCR Global, Tamarac, Florida, United States
- Illinois Cancer Specialists, Arlington Heights, Illinois, United States
- Community MD Anderson Cancer Center - East Medical Oncology, Indianapolis, Indiana, United States
- Maryland Oncology Hematology, Columbia, Columbia, Maryland, United States
- Karmanos Cancer Institute, Detroit, Michigan, United States
- Presbyterian Healthcare Services, Albuquerque, New Mexico, United States
- Icahn School of Medicine at Mount Sinai, New York, New York, United States
- Memorial Sloan-Kettering Cancer Center, New York, New York, United States
- Taylor Cancer Research Center, Maumee, Ohio, United States
Other microbiome trials you might be interested in
Metastatic Non-Squamous Non-Small Cell Lung CancerAdult Solid Tumor
This is an exploratory, signal-finding, randomized, placebo-controlled, blinded, multi-center phase 2b trial of the anti…
Birmingham, United StatesEst. completion Oct 1, 2029
Small Cell Lung Cancer
Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to …
New Haven, United StatesEst. completion May 2029
Alliance Cancer Specialists, PC, Wynnewood, Wynnewood, Pennsylvania, United StatesSarah Cannon Research Institute at Mary Crowley, Dallas, Texas, United StatesThe University of Texas MD Anderson Cancer Center, Houston, Texas, United StatesTexas Oncology - Plano West, Plano, Texas, United StatesVirginia Cancer Specialists, PC, Fairfax, Virginia, United StatesMacquarie University, Macquarie Park, New South Wales, AustraliaGenesisCare North Shore, St Leonards, New South Wales, AustraliaPrincess Alexandra Hospital, Woolloongabba, Queensland, AustraliaSt John of God Subiaco Hospital, Subiaco, Western Australia, AustraliaCancer Research South Australia, Adelaide, AustraliaCliniques Universitaires Saint-Luc, Brussels, BelgiumEdegem - UNIV UZ Antwerpen, Edegem, BelgiumCross Cancer Institute (University of Alberta), Edmonton, Alberta, CanadaBC Cancer Agency - Vancouver, Vancouver, British Columbia, CanadaPrincess Margaret Cancer Centre, Toronto, Ontario, CanadaCentre Hospitalier de l'Universite de Montreal (CHUM), Montreal, Quebec, CanadaMcGill University Health Centre (MUHC), Montreal, Quebec, CanadaPeking University First Hospital, Beijing, ChinaSir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, ChinaAnhui Provincial Cancer Hospital, Hefei, ChinaThe First Affiliated Hospital of Nanchang University, Nanchang, ChinaShanghai East Hospital, Shanghai, ChinaShanghai GoBroad Cancer Hospital, Shanghai, ChinaWuhan Union Hospital, Wuhan, ChinaHenan Cancer Hospital, Zhengzhou, ChinaINS Bergonie, Bordeaux, FranceCTR Georges-François Leclerc, Dijon, FranceCTR Leon Berard, Lyon, FranceHOP Timone, Marseille, FranceHOP la Milétrie, Poitiers, FranceInstitut Gustave Roussy, Villejuif, FranceCharité - Universitätsmedizin Berlin, Berlin, GermanyJustus-Liebig Universität Gießen, Giessen, GermanyAsklepios Kliniken GmbH & Co. KGaA, Hamburg, GermanyUniversität Leipzig, Leipzig, GermanyUniversitätsklinikum Mannheim GmbH, Mannheim, GermanyKlinikum rechts der Isar der Technischen Universität München, München, GermanyAz. Ospedaliere Umberto I di Ancona, Ancona, ItalyCentro di riferimento Oncologico, Aviano (PN), ItalyIstituto Scientifico Romagnolo, Meldola (FC), ItalyASST Grande Ospedale Metropolitano Niguarda, Milan, ItalyAOU Università degli Studi della Campania Luigi Vanvitelli, Naples, ItalyFondazione Policlinico Universitario Campus Bio-medico, Rome, ItalyAichi Cancer Center Hospital, Aichi, Nagoya, JapanNational Cancer Center Hospital East, Chiba, Kashiwa, JapanKyushu University Hospital, Fukuoka, Fukuoka, JapanHokkaido University Hospital, Hokkaido, Sapporo, JapanOkayama University Hospital, Okayama, Okayama, JapanOsaka International Cancer Institute, Osaka, Osaka, JapanShizuoka Cancer Center, Shizuoka, Sunto-gun, JapanNational Cancer Center Hospital, Tokyo, Chuo-ku, JapanJapanese Foundation for Cancer Research, Tokyo, Koto-ku, JapanNederlands Kanker Instituut, Amsterdam, NetherlandsRadboud Universitair Medisch Centrum, Nijmegen, NetherlandsOslo Universitetssykehus HF, Radiumhospitalet, Oslo, NorwayPan American Center for Oncology Trials, LLC, Rio Piedras, Puerto RicoNational Cancer Centre Singapore, Singapore, SingaporeSeoul National University Hospital, Seoul, South KoreaSeverance Hospital, Seoul, South KoreaAsan Medical Center, Seoul, South KoreaSamsung Medical Center, Seoul, South KoreaComplejo Hospitalario Universitario A Coruña, A Coruña, SpainHospital Germans Trias i Pujol, Badalona, SpainHospital del Mar, Barcelona, SpainHospital Universitari Vall d'Hebron, Barcelona, SpainHospital Duran i Reynals, Barcelona, SpainClínica Universidad de Navarra - Madrid, Madrid, SpainHospital Clínico San Carlos, Madrid, SpainClínica Universidad de Navarra, Pamplona, SpainHospital Virgen del Rocío, Seville, SpainHospital Clinico De Valencia (INCLIVA), Valencia, SpainNinewells Hospital & Medical School, Dundee, United KingdomThe Christie Hospital, Manchester, United KingdomGEP-NETGastroenteropancreatic Neuroendocrine TumorGastroenteropancreatic Neuroendocrine Tumor DiseaseNeuroendocrine TumorsCarcinoidCarcinoid TumorPancreatic NETSolid TumorSomatostatin Receptor
The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize …
Iowa City, United StatesEst. completion Feb 2027